Donepezil for the treatment of behavioral symptoms in patients with Alzheimer's disease
| Autor: | Doron Mazeh, Yoram Barak, Michael Even, Ilona Mirecki, Diana Paleacu |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Male
medicine.medical_specialty Behavioral Symptoms Neuropsychological Tests Irritability Piperidines Alzheimer Disease Internal medicine medicine Dementia Outpatient clinic Humans Pharmacology (medical) Donepezil Adverse effect Aged Pharmacology Aged 80 and over Mini–Mental State Examination medicine.diagnostic_test business.industry medicine.disease Surgery Diagnostic and Statistical Manual of Mental Disorders Indans Clinical Global Impression Female Neurology (clinical) Cholinesterase Inhibitors medicine.symptom Alzheimer's disease business Mental Status Schedule medicine.drug Follow-Up Studies |
| Zdroj: | Clinical neuropharmacology. 25(6) |
| ISSN: | 0362-5664 |
| Popis: | Behavioral and psychologic symptoms of dementia (BPSD) are common manifestations in mid- and late-stage Alzheimer's disease (AD). Traditional treatments for BPSD are neuroleptics and sedatives, which are not devoid of serious adverse effects. A number of studies show beneficial effects in the treatment of BPSD with acetylcholinesterase inhibitors (AChEI). The present study aimed to evaluate the effect of donepezil (using the generic drug Memorit) as monotherapy for AD patients suffering from BPSD. Twenty-eight consecutive patients followed at the Memory Outpatient Clinic and Psychogeriatric Department of the Abarbanel Mental Health Center were treated with donepezil for 6 months. Starting dose was 5 mg daily during the first 4 weeks and continuation with 10 mg daily thereafter. Treatment effects were evaluated using the Mini Mental State Examination (MMSE), the Neuro-Psychiatric Inventory (NPI), and the Clinical Global Impression of Change Scale (CGIC) caregiver version. Twenty-four of 28 patients completed the study. Of these, five patients needed additional rescue neuroleptic treatment due to incomplete response. The mean dose of donepezil was 9.10 mg/day (median 10 mg/day). The overall NPI improved significantly from 33.4 to 21.2 (p = 0.008). The mean CGIC at study's end was 3.0 (mild improvement). The cognitive scores did not change significantly. When compared to the patients who completed the study, patients who discontinued had higher mean scores on the irritability and agitation subscales of the NPI, they were older, and they had longer disease duration and lower MMSE mean scores. Three adverse events were recorded: one syncope causing a toe phalanx fracture and gastrointestinal complaints that resolved over time in two additional patients. Acetylcholinesterase inhibitors should be considered for the treatment of BPSD before neuroleptic treatment is instituted in AD patients with low levels of irritability and agitation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|